Cargando…

δ-Catenin Increases the Stability of EGFR by Decreasing c-Cbl Interaction and Enhances EGFR/Erk1/2 Signaling in Prostate Cancer

δ-Catenin, a member of the p120-catenin subfamily of armadillo proteins, reportedly increases during the late stage of prostate cancer. Our previous study demonstrates that δ-catenin increases the stability of EGFR in prostate cancer cell lines. However, the molecular mechanism behind δ-catenin-medi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shrestha, Nensi, Shrestha, Hridaya, Ryu, Taeyong, Kim, Hangun, Simkhada, Shishli, Cho, Young-Chang, Park, So-Yeon, Cho, Sayeon, Lee, Kwang-Youl, Lee, Jae-Hyuk, Kim, Kwonseop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Molecular and Cellular Biology 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935102/ https://www.ncbi.nlm.nih.gov/pubmed/29629558 http://dx.doi.org/10.14348/molcells.2018.2292

Ejemplares similares

Interaction of EGFR to δ-catenin leads to δ-catenin phosphorylation and enhances EGFR signaling
por: He, Yongfeng, et al.
Publicado: (2016)

Effects of δ-Catenin on APP by Its Interaction with Presenilin-1
por: Dai, Weiye, et al.
Publicado: (2019)

δ-Catenin Participates in EGF/AKT/p21(Waf) Signaling and Induces Prostate Cancer Cell Proliferation and Invasion
por: Shen, Yingjie, et al.
Publicado: (2021)

14-3-3ɛ/ζ Affects the stability of δ-catenin and regulates δ-catenin-induced dendrogenesis()
por: He, Yongfeng, et al.
Publicado: (2012)

Regulation of EGFR Endocytosis by CBL During Mitosis
por: Wee, Ping, et al.
Publicado: (2018)

p300/CBP-associated factor promotes autophagic degradation of δ-catenin through acetylation and decreases prostate cancer tumorigenicity
por: Zhou, Rui, et al.
Publicado: (2019)

Dual-specificity phosphatase 5 acts as an anti-inflammatory regulator by inhibiting the ERK and NF-κB signaling pathways
por: Seo, Huiyun, et al.
Publicado: (2017)

Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and β-Catenin Signaling
por: Yawut, Natpaphan, et al.
Publicado: (2020)

Knockout of c‐Cbl slows EGFR endocytic trafficking and enhances EGFR signaling despite incompletely blocking receptor ubiquitylation
por: Crotchett, Brandon L. M., et al.
Publicado: (2021)

c-Cbl、Cbl-b和EGFR在非小细胞肺癌中的表达及其预后价值
Publicado: (2011)

CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
por: Tan, Yi-Hung Carol, et al.
Publicado: (2010)

Simulating EGFR-ERK Signaling Control by Scaffold Proteins KSR and MP1 Reveals Differential Ligand-Sensitivity Co-Regulated by Cbl-CIN85 and Endophilin
por: Huang, Lu, et al.
Publicado: (2011)

Anti-Cancer Effects of Glaucarubinone in the Hepatocellular Carcinoma Cell Line Huh7 via Regulation of the Epithelial-To-Mesenchymal Transition-Associated Transcription Factor Twist1
por: Seo, Jihye, et al.
Publicado: (2021)

Correction: CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
por: Tan, Yi-Hung Carol, et al.
Publicado: (2011)

Scaffold Role of DUSP22 in ASK1-MKK7-JNK Signaling Pathway
por: Ju, Anna, et al.
Publicado: (2016)

Cbl-b Enhances Sensitivity to 5-Fluorouracil via EGFR- and Mitochondria-Mediated Pathways in Gastric Cancer Cells
por: Feng, Dan, et al.
Publicado: (2013)

δ-Catenin promotes prostate cancer cell growth and progression by altering cell cycle and survival gene profiles
por: Zeng, Yan, et al.
Publicado: (2009)

RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation
por: Cho, Jung Hee, et al.
Publicado: (2018)

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
por: Jung, Minkyu, et al.
Publicado: (2012)

Ectopic Expression of SjCBL1, Calcineurin B-Like 1 Gene From Sedirea japonica, Rescues the Salt and Osmotic Stress Hypersensitivity in Arabidopsis cbl1 Mutant
por: Cho, Joo Hyuk, et al.
Publicado: (2018)

The von Hippel-Lindau Tumor Suppressor Protein Promotes c-Cbl-Independent Poly-Ubiquitylation and Degradation of the Activated EGFR
por: Zhou, Liang, et al.
Publicado: (2011)

D-Cbl Binding to Drk Leads to Dose-Dependent Down-Regulation of EGFR Signaling and Increases Receptor-Ligand Endocytosis
por: Wang, Pei-Yu, et al.
Publicado: (2011)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
por: Arasada, Rajeswara Rao, et al.
Publicado: (2018)

Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
por: So, Kwang Sup, et al.
Publicado: (2014)

Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway
por: Orton, Richard J, et al.
Publicado: (2009)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
por: Park, Keunchil, et al.
Publicado: (2021)

Bisecting N-Acetylglucosamine on EGFR Inhibits Malignant Phenotype of Breast Cancer via Down-Regulation of EGFR/Erk Signaling
por: Cheng, Lanming, et al.
Publicado: (2020)

Convergence between Wnt-β-catenin and EGFR signaling in cancer
por: Hu, Tianhui, et al.
Publicado: (2010)

Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer
por: Lee, Sangah, et al.
Publicado: (2021)

BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level
por: Kim, Ji Hye, et al.
Publicado: (2021)

Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency
por: Huemer, Martina, et al.
Publicado: (2016)

Morphine promotes microglial activation by upregulating the EGFR/ERK signaling pathway
por: Yang, Yaqiong, et al.
Publicado: (2021)

Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2020)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
por: Jun, Sei-Yong, et al.
Publicado: (2022)

A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification
por: Choi, Seung Won, et al.
Publicado: (2023)

Phosphorylation of PKCδ by FER tips the balance from EGFR degradation to recycling
por: Lonic, Ana, et al.
Publicado: (2021)

Bromopropane Compounds Increase the Stemness of Colorectal Cancer Cells
por: Cho, Young-Chang, et al.
Publicado: (2017)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
por: Cho, Jaeyoung, et al.
Publicado: (2016)

Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2
por: Bae, Kieun, et al.
Publicado: (2022)

Euphorbiasteroid Abrogates EGFR and Wnt/β-Catenin Signaling in Non-Small-Cell Lung Cancer Cells to Impart Anticancer Activity
por: Kim, Na Young, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6q8m662g4mrqv9ncfdbpmhrfli